Comparing the effects of fluticasone, anti-IgE and anti-TNF treatments in a chronic asthma model
Main Article Content
Keywords
Anti-IgE, Anti-TNF, Asthma, Fluticasone, IgE, IL-4, Lung histopathology, miRNA-126, miRNA-133a
Abstract
Background: Corticosteroids are used in the treatment of asthma. The aim of this study was to determine the efficacy of anti-IgE and anti-TNF alpha as asthma treatments.
Methods: A mouse model of chronic asthma was developed. The fluticasone group was exposed to fluticasone and the anti-IgE and anti-TNF groups were administered anti-IgE or anti-TNF. IL-4, and IgE levels were measured, and histological analysis, pathological analysis and miRNA-126, miRNA-133a analyses were applied.
Results: The cell concentration in the BAL fluid decreased in all the treatment groups. The rate of perivascular and peribronchial cell infiltration decreased in the lung in the high-dose anti-IgE and anti-TNF groups. Smooth muscle thickness decreased in the lung tissue in the low-dose anti-IgE and anti-TNF groups. Bronchial wall thickness decreased in the lung tissue in the fluticasone + anti-IgE group. The IL-4 level in BAL fluid decreased in the high-dose anti-IgE, fluticasone + anti-IgE and anti-TNF groups. IgE levels increased in the BAL fluid in the high-dose anti-IgE and anti-TNF groups. The lymphocyte level increased in the BAL fluid in the high-dose anti-IgE group. The macrophage level decreased in the BAL fluid in the anti-TNF group. The relative expression of miRNA-126 increased in all groups. The relative expression of miRNA-133a decreased in the placebo and fluticasone groups. The relative expression of miRNA133a increased in the low-dose anti-IgE, high-dose anti-IgE, fluticasone + anti-IgE and anti-TNF groups.
Conclusions: The results showed that anti-IgE is successful as a treatment. Fluticasone + antiIgE and anti-TNF were seen to be superior to other therapeutic modalities when used for prophylaxis.
References
2. European Academy of Allergy and Clinical Immunology. Global atlas of asthma; 2013. Available at: www.eaaci.org [accessed August 2013].
3. Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, et al. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol. 2012;130:563-71, http://dx.doi.org/10.1016/j.jaci.2012.07.027.
4. Hutchison S, Choo-Kang BSW, Bundick RV, Leishman AJ, Brewer JM, McInnes IB, et al. Tumour necrosis factor-alfa blockade suppresses murine allergic airways inflammation. Br Soc Immunol Clin Exp Immunol. 2007;151:114-22, http://dx.doi.org/10.1111/j.1365-2249.2007.03509.x.
5. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549-58, http://dx.doi.org/10.1164/rccm.200809-1512OC.
6. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax. 1998;53:849-56, http://dx.doi.org/10.1136/thx.53.10.849.
7. Herz U, Lumpp U, Da Palma JC, Enssle K, Takatsu K, Schnoy N, et al. The relevance of murine animal models to study the development of allergic bronchial asthma. Immunol Cell Biol. 1996;74:209-17, http://dx.doi.org/10.1038/icb.1996.30.
8. Uzuner N, Kavukcu S, Yilmaz O, Ozkal S, Is¸lekel H, Karaman O, et al. The role of l-carnitine in treatment of a murine model of asthma. Acta Med Okayama. 2002;56:295-301.
9. Riesenfeld EP, Sullivan MJ, Thompson-Figueroa JA, Haverkamp HC, Lundblad LK, Bates JHT, et al. Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res. 2010;11:22, http://dx.doi.org/10.1186/1465-9921-11-22.
10. Patterson CM, Morrison RL, D’Souza A, Teng XS, Happel KI. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella Pneumoniae in mice. Respir Res. 2012;13:40, http://dx.doi.org/10.1186/1465-9921-13-40.
11. Kang JY, Kim JW, Kim JS, Kim SJ, Lee SH, Kwon SS, et al. Inhibitory effects of anti-immunoglobulin E antibodies on airway remodeling in a murine model of chronic asthma. J Asthma. 2010;47:374-80, http://dx.doi.org/10.3109/02770901003801972.
12. Deveci F, Muz HM, Ilhan N, Kirkil G, Turgut T, Akpolat N. Evaluation of the anti-inflammatory effect of infliximab in a Mouse model of acute asthma. Respirology. 2008;13:488-97, http://dx.doi.org/10.1111/j.1440-1843.2008.01278.x.
13. McMillan SJ, Xanthou G, Lloyd CM. Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling. Clin Exp Allergy. 2005;35:388-96, http://dx.doi.org/10.1111/j.1365-2222.02193.x.
14. Heialy SA, McGovern TK, Martin JG. Insights into asthmatic airway remodeling through murine models. Respirology. 2011;16:589-97, http://dx.doi.org/10.1111/j.1440-1843.2011.01974.x.
15. Hansel TT, Barnes PJ. Novel drugs for treating asthma. Curr Allergy Asthma Rep. 2001;1:164-73, http://dx.doi.org/10.1007/s11882-001-0084-5.
16. Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, et al. Early thickening of the reticular basement in children with
difficult asthma. Am J Respir Crit Care Med. 2003;167:78-82, http://dx.doi.org/10.1164/rccm.200205-414OC.
17. Frieri M. Advances in the understanding of allergic asthma. Allergy Asthma Proc. 2007;28:614-9, http://dx.doi.org/10.2500/aap.2007.28.2952.
18. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patient. Chest. 1998;113:578-92, http://dx.doi.org/10.1378/chest.113.3.587.
19. Chan PW, DeBruyne JA. Parental concern towards the use of inhaled therapy in children with chronic asthma. Pediatr Int. 2000;42:547-51, http://dx.doi.org/10.1046/j.1442-200x. 2000.01278.x.
20. Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, et al. Monoclonal anti-TNF- antibodies for severe steroid-dependent asthma: a case series. Open Respir Med J. 2013;7:21-5, http://dx.doi.org/10.2174/1874306401307010021.
21. Ernst E. Complementary therapies for asthma: what patients use? J Asthma. 1998;35:667-71, http://dx.doi.org/10.3109/02770909809048969.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.